All posts by imreal

Health

HIMSS Analytics Survey Sponsored by Dimensional Insight Finds Healthcare Orgs. that Focus on Clinical Outcomes as Key ROI Metric Have Higher Success with Analytics

Leave a comment


As healthcare organizations move to value-based payment models, they are finding that focusing on clinical metrics, including readmission rates, infection control, and patient outcome improvements is critical for success. Analytics provides tremendous insight into these areas.


BURLINGTON, Mass. (PRWEB)

Dimensional Insight®, the maker of Diver Platform™, a data management, analytics, and performance management solution, today announced the results of a survey it conducted with HIMSS Analytics of 109 senior healthcare leaders. The survey examined how healthcare organizations implement metrics and measure ROI from their analytics programs. It found that those organizations that focus on clinical outcomes as their key ROI metric – as opposed to financial returns or staff efficiency – rank higher across the board in terms of usage of analytics across the organization, average number of metrics used, measured success rate, and overall effectiveness of analytics.

“As healthcare organizations move to value-based payment models, they are finding that focusing on clinical metrics, including readmission rates, infection control, and patient outcome improvements is critical for success,” says George Dealy, vice president of healthcare solutions at Dimensional Insight. “Analytics provides tremendous insight into these areas and can benefit healthcare organizations that are navigating this transition.”

Key findings from the survey include:

  • Of organizations that are leveraging analytics, 84% are doing so in multiple areas (clinical, financial, operational), while two-thirds are leveraging analytics across the organization.

  • Organizations feel their analytics solutions have been most effective towards improving financial performance, but they have been able to see the most measured success with clinical analytics (77.7%) vs. financial analytics (73.5%) or operational analytics (70.3%).

  • The primary method organizations use to determine ROI is most often financial returns and improvements (41.2%) vs. clinical outcome improvement (37.3%), staff efficiency (12.7%), or measured improvements across the patient journey (3.9%). However, they see the highest measured success rate (75.4%) if they use clinical outcomes improvement as their primary metric.


To learn more, download the full survey results at: https://www.dimins.com/HIMSSsurvey19

About Dimensional Insight

Dimensional Insight® is a leading provider of analytics, data management, and performance management solutions, offering a complete portfolio of capabilities ranging from data integration and modeling to sophisticated reporting, analytics, and dashboards. The company is a six-time Best in KLAS winner in healthcare business intelligence and analytics, most recently ranking #1 in 2019. Founded in 1989, Dimensional Insight has thousands of customer organizations worldwide. Dimensional Insight consistently ranks as a top performing analytics organization by customers and industry analysts in its core market segments including healthcare, manufacturing, and beverage alcohol. For more information, please visit https://www.dimins.com.

Share article on social media or email:

Science: Biology

Leak Detection Associates to Serve as Key Supplier and Technical Presenter at the PDA CCIT Training Course

Leave a comment


Leak Detection Associates at PDF 2019 The Universe of Pre-filled Syringes and Injection Devices

We are extremely excited to be included in this highly educational event specific to the key testing methods for container and package integrity testing


EGG HARBOR TOWNSHIP, N.J. (PRWEB)

Leak Detection Associates, the leading global supplier of helium based leak detection systems for the Pharmaceutical, Biotechnology and Medical Device Industries, is excited to announce that it will be a contributing instrument manufacturer and technical presenter at the Parenteral Drug Association (PDA) Container Closure Integrity Testing Training Course. Held in conjunction with PDA Europe’s Universe of Pre-Filled Syringe Conference, the two-day training program encompasses presentations on theory and real-life applications of all deterministic container closure integrity test (CCIT) technologies referenced in USP 1207. Critically, participating attendees are given the opportunity to witness demonstrations of actual instrumentation, with the unique opportunity for hands-on use in an engaging and learning-based environment.

The PDA Universe of Pre-Filled Syringe Conference will be held in Gothenburg, Sweden the week of October 21, 2019 and the CCI specific training course is scheduled for October 24th and 25th. Presenting on behalf of Leak Detection Associates will be Brandon Zurawlow, the lead CCI Principal for Containsure, while Jeff Morrow Lucas, LDA’s Director of Engineering, will host the hands-on technical training for attendees. In support of these technical presentations and hands-on activities, Leak Detection Associates will be providing its newest model, the SIMS 1915+ Helium Leak Detection System. Attendees will gain an understanding of how the system can be used to establish inherent integrity, optimize manufacturing, and more for a range of package systems and at extreme levels of sensitivity. LDA will also be featuring its new, low temperature add-on system that enables analysis of packages down to -80°C, critical for product-packages stored at these aggressive temperatures.

“We are extremely excited to be included in this highly educational event to specifically represent a key test method for container and package integrity testing,” commented Brian Mulhall, LDA’s CEO. “For more than 20 years, Leak Detection Associates has held a leadership role in the development and use of helium technology for container leak testing and having the opportunity to advance our knowledge and experience as part of a unique training seminar such as this will enable the value of helium leak testing to be shared with many relevant participants who are looking for CCI solutions in this highly regulated area.”

This course focuses on theoretical and practical fundamentals of various CCI testing technologies and provides a systematic approach to apply these testing methods for CCI verification throughout drug product lifecycles. The course, as a whole, will enable the participants to implement CCI testing strategies to ensure adequate drug product protection and be compliant with relevant regulatory and compendial requirements. In this course, participants gain critical problem-solving skills through:


  • Interactive discussions with a panel of cross-functional technical experts consisting of CCI testing laboratory experts, testing instrument suppliers/manufacturers, and pharmaceutical packaging development engineers

  • Hands-on testing training on the newest innovations and state-of-the-art instruments

  • Real-world case studies

Being held in conjunction with the Universe of Pre-Filled Syringe meeting, this training course will utilize lectures, case studies, and interactive hands-on training on testing instruments to provide insight into the latest developments of Container Closure Integrity (CCI) Testing. It is expected that participants will develop an understanding of the most up-to-date regulatory and pharmacopeia requirements on CCIT while learning how to define CCI requirements for various container and drug product types using a risk-based approach. The key focus will be on practical applications using the deterministic methods such as tracer gas detection (e.g. helium leak detection), electrical conductivity and capacitance (HVLD), vacuum decay leak detection, laser-based gas headspace analysis, and mass extraction leak tests. Other key topic areas to be covered include selecting and applying appropriate testing methods for both laboratory and in-process testing to formulate comprehensive package integrity verification profiles, defining CCI testing method development and validation approaches and best practices, and avoiding common issues and pitfalls in CCI testing applications. To learn more about the conference and to register for attendance at this valuable training course, please visit http://www.pda.org.

About Leak Detection Associates, LLC

For over 20 years, Leak Detection Associates has been the premier manufacturer of custom helium leak detection instruments for the pharmaceutical, biotechnology, medical device and food packaging industries. LDA’s well-established technology has been incorporated into ASTM and compendial guidance documents. This robust industry experience, combined with the advanced capabilities of its newest model, the SIMS 1915+ helium leak detection unit, provides companies with tools to quantitatively evaluate leakage, improve the package development cycle, establish manufacturing controls, and ultimately reduce risk to the product and consumer throughout the lifecycle.

Share article on social media or email:

Technology: Electronics

MultiLane Chooses Amphenol Ardent Concepts for 400G Module Compliance Boards

Leave a comment


The combination of these two innovative products has given the manufacturing test market one of the most compelling MCBs on the market.


HAMPTON, N.H. (PRWEB)

MultiLane’s module compliance boards are fully featured, CMIS compliant and low-loss, making them ideal for optical transceiver testing. These boards are now paired with Amphenol Ardent Concepts’ replaceable, multi-channel TR Multicoax Series connectors, resulting in an extremely low-cost, consumable MCB for high volume testing.

The key features of this combination include programming and testing of 400G QSFP-DD/OSFP transceivers and active optical cables. Additionally, it boasts a user-friendly GUI supporting all features defined by QSFP-DD/OSFP MSA. MultiLane’s board is ideal for transceiver manufacturing testing, optical transmitter testing, receiver sensitivity, electrical interface testing, and thermal testing of transceivers. MultiLane’s ML4062-TR (QSFP-DD MCB) and ML4064-TR (OSFP MCB) can also be used in conjunction with ML4066 analyzer boards to enable low speed I2C CMIS testing, in addition to abovementioned capabilities.

Two TR Multicoax Series connectors are needed for each compliance board. This connector delivers superior signal integrity from multiple high-speed analog or digital channels. With a choice of 20 GHz, 40 GHz, or 70 GHz configurations, users can upgrade their connectors as bandwidth requirements on their applications increase. TR utilizes Amphenol Ardent Concepts’ patented solderless technology, encouraging cost savings and reusability across multiple programs.

The combination of these two innovative products has given the manufacturing test market one of the most compelling MCBs on the market. Low-cost, reusability, high density, and excellent signal integrity are incredibly beneficial to test and measurement, and this board provides all of them.

MultiLane will be running a live demonstration of this module compliance board at the European Conference on Optical Communication in Dublin September 23-25 at Booth #481.

Amphenol Ardent Concepts is a leading designer and manufacturer of high performance multicoax and coaxial assemblies, connectors, and sockets used in the development of next generation semiconductors and electronics systems. Our core technology is one of the smallest, fastest, most electrically efficient compression mount connector technologies commercially available. As data rate requirements increase and devices and systems shrink, Amphenol Ardent’s products deliver superior signal integrity in a dense footprint that can be reusable across programs to maximize cost savings.

MultiLane, a leading provider of T&M equipment for production testing, develops instruments and interconnects for 10 to 400 Gb/s data rates. Products include BERTs, TDR, optical and electrical oscilloscopes, optical switch boxes, and a host of MSA-compliant development tools for QSFP28, QSFP-DD, OSFP, and other standards. The company also offers compliance test services and fully automated test solutions. In addition, MultiLane develops high speed ATE modules that fit in wafer-scale automated test systems such as Advantest’s V93K platform. MultiLane’s products are used to test semiconductors, DACs, transceivers, and system blades. More information can be found at http://www.multilaneinc.com.

Share article on social media or email:

Industry: Healthcare

3Lions Publishing, Inc. Announces Release 2.5 of Expresso®: Breach Notification Wizard

Leave a comment


https://www.prweb.com/

Online Publishing Done Right!

What QBO did for accounting Expresso® 2.5 does for Risk Assessments and Breach Notification. Transforming these processes into something that a business person can master at some basic to intermediate level.


TAMPA, Fla. (PRWEB)

3Lions Publishing, Inc. (3LP), the owner/operator of the HIPAA Survival Guide, is pleased to announce Release 2.5 of Expresso® featuring our Breach Notification Wizard. Expresso® 2.5 is available for purchase on the HIPAA Survival Guide Store as part of our HIPAA Compliance Subscription Plan. Expresso® is our software-as-a-service offering which embodies the NIST seven (7) step process for performing Risk Assessments and is now poised to save our customers hundreds of person hours by identifying when Breach Notification is triggered and gathering the requisite information necessary to Notify stakeholders under applicable Federal/State law.

Our Wizard contains a Jurisdictions table that enables you to quickly determine the Notification requirements of all U.S. States/Territories that may have been impacted by the Breach. It also performs the necessary “Notification math” that determines when HHS is notified, depending on how many patients were impacted across Jurisdictions and when “major media” is notified, depending on how many patients were impacted within a Jurisdiction.

Carlos Leyva, CEO of 3Lions Publishing, Inc., says: “What QuickBooks Online (“QBO”) did for accounting Expresso® 2.5 does for Risk Assessments and Breach Notification. QBO did not eliminate all the work associated with accounting, however it transformed accounting from a necessary evil, something to be avoided at all costs and/or handed over to a third party, to something that a business person could master at some basic to intermediate level. With the Release of Expresso® 2.5 3Lions continues to deliver on the promise of Enterprise Compliance for the Masses.”

Covered entities no longer need to fear willful neglect for lack of visible, demonstrable evidence of a Risk Assessment. Further, our Wizard, together with our Breach Notification Framework and our Breach Response Framework, will save your organization tens of thousands of dollars when (not if) your organization experiences a Breach. Although Expresso® does not completely obviate the need for counsel, it will save you hundreds of person-hours of billable time.

About 3Lions Publishing, Inc. (3LP)

3LP focuses on publishing online curated content within well-defined subject matter domains, such as healthcare. 3LP helps publishers leverage and monetize their content by providing a publishing platform that matches high quality content with a digital marketing centric set of audience development tools. 3LP is located in the greater Tampa, FL area.

Share article on social media or email:

Business: Insurance

The Impact of the Community Rating System

Leave a comment


News Image


MILWAUKEE (PRWEB)

Hurricanes Sandy and Katrina reeked havoc on our southern and eastern coastlines. With recent flooding along the Mississippi River and the near-miss of Hurricane Barry on the Gulf Coast is a reminder of the constant flood risk faced by communities and the need to be prepared for flood events.

In a new article released in the Applied Economic Perspectives & Policy, “Flood Insurance and Claims: The Impact of the Community Rating System,” Eugene Frimpong from East Carolina University and Ardian Harri, Daniel Petrolia, and John Cartwright from Mississippi State University look into what it would take to increase participation in the National Flood Insurance Program (NFIP).

Petrolia says, “We find a positive relationship between participation in the Community Rating System (CRS) and participation in the NFIP. However, we find that only those communities participating at the highest levels of the CRS realize real reductions in flood claims. So the policy discounts associated with CRS participation appear to be attracting more homeowners to insure, but only in very limited cases do the levels (and types) of CRS participation appear to lead to real reductions in exposure.

If you are interested in setting up an interview with Petrolia, please contact Allison Scheetz in the AAEA Business Office.

About AAEA: Established in 1910, the Agricultural & Applied Economics Association (AAEA) is the leading professional association for agricultural and applied economists, with 2,500 members in more than 60 countries. Members of the AAEA work in academic or government institutions as well as in industry and not-for-profit organizations, and engage in a variety of research, teaching, and outreach activities in the areas of agriculture, the environment, food, health, and international development. The AAEA publishes two journals, the American Journal of Agricultural Economics and Applied Economic Perspectives & Policy, as well as the online magazine Choices and the online open access publication series Applied Economics Teaching Resources. To learn more, visit http://www.aaea.org.

Share article on social media or email:

Business: Executives

C.A. Short Company Expands Executive Team, Appoints Christopher Cheney Chief Operating Officer

Leave a comment


https://www.prweb.com/

Christopher Cheney


CHARLOTTE, N.C. (PRWEB)

C.A. Short Company, a leading provider of recognition and engagement solutions, today announced the appointment of Christopher Cheney to the role of Chief Operating Officer. With extensive management experience, Cheney brings valuable leadership to C.A. Short’s executive team during a period of rapid growth. As COO, Cheney will lead operations and direct the company’s customer experience, merchandising and sourcing, implementation, technology and logistical/fulfillment functions.

Jeff Ross, CEO & CFO of C.A. Short had this to say regarding Cheney’s addition, “We are very fortunate to have someone of Christopher’s caliber, experience and proven track record of execution to join our team. We are at a major point in our growth and Christopher’s leadership will be an integral part in successfully implementing our strategy and taking advantage of the market opportunities ahead. We could not be more excited here at C.A. Short Company. Let’s go!!”

Prior to joining C.A. Short, Cheney acted as Senior Vice-President of Operations for Inspirus, a Sodexo Company, in southeast Texas. There he put his expertise to work optimizing company processes and boosting product capacities. Cheney has more than twenty-five years of experience in the recognition industry and will bring a wealth of knowledge to C.A. Short Company.

Cheney is a graduate of the University of Massachusetts Dartmouth. He is a Six Sigma Green Belt with additional certifications in Lean and DFSS.

About C.A. Short Company

C.A. Short offers industry leading recognition, engagement and incentive solutions through innovative design, rapid implementation, and “all-in” exceptional service, delivering positive behavior changes and measurable, impactful business results.

http://www.cashort.com

Share article on social media or email:

Health

We Will Fight Purdue Settlement on Behalf of Opioid-Dependent Babies

Leave a comment


“This fight is not over, nor should it be.” – Celeste Brustowicz


NEW ORLEANS (PRWEB)

Attorneys, medical experts and non-profit leaders represented by the Opioid Justice Team and more than 35 class actions representing infants born already opioid-dependent due to the mother’s use of prescription opioids while pregnant, intend to fight vigorously Purdue Pharma’s efforts to shield itself from thousands of lawsuits filed in relation to America’s prescription opioid crisis, fueled in large part by the marketing of Purdue’s OxyContin drug.

“Our clients, the innocent victims of this nation’s unbridled corporate promotion of an addictive substance to thousands of men and women, but especially child-bearing aged women, will not accept the bankruptcy settlement,” said Lead Attorney Celeste Brustowicz. “This proposal ignores the most critical victims of this crisis, who will suffer birth defects like Spina Bifuda and Gillam-Barre, and very often be sent home from hospitals as opioid-free babies with unsuspecting parents who may not see developmental disabilities in these children for months.”

According to a settlement announced Sunday, Purdue hopes Chapter 11 bankruptcy will prompt an automatic stay of current civil litigation against the company over the opioid epidemic. Though Purdue estimates the value of the settlement at $10 billion, others with a vested interest in the proposal believe this is too optimistic a calculation and could be worth only half that much. Others oppose the deal because the restructured company proposed in the settlement allows on-going sales of OxyContin to fund the settlement structure, rather than the existing profits of Purdue’s owners themselves.

“After two decades of indiscriminate destruction and devastation to families nationwide, it is insincere for Purdue to declare in the days preceding its bell-weather trial in Cleveland, that it and the Sackler family alike are in a rush to get money to the politicians, whether it be the states, counties or cities,” said Ms. Brustowicz. “Purdue voluntarily surrendering itself by agreeing to enjoin themselves from engaging in misconduct is unprecedented, even by Purdue’s own lawyers.”

Currently, cases against Purdue because of the prescription opioid crisis linked to drug manufacturer and distributor falsehoods and suspect marketing practices, number in the millions of individuals. Among these are at least 250,000 infants represented by the Opioid Justice Team. These attorneys and medical experts fighting on behalf of opioid-dependent infants estimate a baby with Neo-Natal Abstinence Syndrome (NAS) is born in the U.S. every 15 minutes.

“This is an insensitive response to children and their guardians. The time for defendants and Big Pharma to make amends with babies suffering from Neo-natal Abstinence Syndrome and related maladies is long overdue,” said Ms. Brustowicz. “This fight is not over, nor should it be.”

Ms. Brustowicz said her team will continue to push for a legal track in the Multi-District Litigation before Judge Polster, whom drug manufacturer representatives moved to have removed from the case over the weekend, as well as in the 35 individual states which have filed NAS class actions.

“We’re on the side of the angels and we will continue to press on,” she said.

Share article on social media or email:

Industry: Healthcare

Roswell Park Moving Unique Immunotherapy Platform Forward With $6.42 Million DoD Grant

Leave a comment


Drs. Shipra Gandhi and Pawel Kalinski will lead a Department of Defense-funded clinical trial assessing a three-pronged immunotherapy strategy for metastatic breast cancer.

Drs. Shipra Gandhi and Pawel Kalinski will lead a Department of Defense-funded clinical trial assessing a three-pronged immunotherapy strategy for metastatic breast cancer.

Our strategy uses a unique combination of biologic agents to make tumors visible to the immune system by making them look like tissue that’s been infected by a virus. Findings from earlier studies lend strong support for assessing this combination even in aggressive and hard-to-treat cancer types.


BUFFALO, N.Y. (PRWEB)

A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a U.S. Department of Defense (DoD) grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Rustum Family Professor for Molecular Therapeutics and Translational Research at the Buffalo, N.Y.-based cancer center. The four-year, $6.42 million Breakthrough Award (award no. W81XWH-19-1-0674/BC180510) through the DoD’s Breast Cancer Research Program will fund a clinical trial in patients with brain-metastatic breast cancer, to be led by Shipra Gandhi, MD, Assistant Professor of Oncology in the Department of Medicine at Roswell Park.

The phase II trial, slated to open in 2020, would be the first clinical study to assess the effectiveness of a three-pronged strategy combining distinct immunotherapy approaches:


  • A new dendritic-cell treatment vaccine developed by Dr. Kalinski and colleagues in collaboration with Brian Czerniecki, MD, PhD, Chair of the Breast Oncology Department at Moffitt Cancer Center in Tampa, Florida

  • Chemokine modulation using a combination proposed and validated by Dr. Kalinski as an optimized adjuvant for dendritic-cell vaccines, incorporating rintatolimod (brand name Ampligen) and interferon alfa-2b (brand name Intron A)

  • Immune checkpoint inhibition

Alone, these therapies are effective for a limited number of patients, but evidence suggests that together they may help break through a persistent challenge in oncology: how to turn “cold” tumors that don’t respond to existing therapies into “hot” ones that the immune system can be trained to recognize and pursue.

“A major limitation of cancer immunotherapy is that tumors adapt to naturally occurring effector cells by shutting down production of the relevant chemokines in the tumor microenvironment,” says Dr. Kalinski, the overall Principal Investigator for the project. “Our strategy uses a unique combination of biologic agents to make tumors visible to the immune system by making them look like tissue that’s been infected by a virus. We’ve never tested them all together before in patients, but the findings from earlier clinical and preclinical studies lend strong support for assessing this combination even in the most aggressive and hard-to-treat cancer types.”

Three key factors distinguish this platform for combination immunotherapy:

  • The approach is tumor-selective, meaning it can act preferentially to generate responses only in cancer tissues, but not in normal, noncancerous tissue

  • It selectively activates so-called “good” chemokines in the tumor microenvironment and promotes selective attraction of desirable tumor-fighting immune cells, but avoids activating “bad” chemokines that attract undesirable suppressive cells

  • These therapies have been shown in preclinical and clinical trials to be associated with low toxicity and few adverse side effects

The team will study this approach first in patients with localized brain-metastatic breast cancer (BMBC), or breast cancer that has begun to spread to the brain but is not yet widely disseminated. A companion clinical trial in patients with disseminated, leptomeningeal BMBC, to be led by Peter A. Forsyth, MD, Chair of the Neuro-Oncology Department at Moffitt Cancer Center, in collaboration with Dr. Czerniecki, partnering Principal Investigator on the project, will move forward with additional DoD funding of more than $8 million. Both trials will be available to patients at Roswell Park and at Moffitt.

“There are currently no curative treatments for breast cancer that has spread to and grown in the brain, and the options we have often involve significant side effects or harm to healthy tissues. So this is an area of pronounced clinical need,” notes Dr. Gandhi, Principal Investigator on the Roswell Park study. “We’re particularly encouraged to be developing a strategy that has the potential to be effective for patients with various breast cancer subtypes — cancers that are positive for HER2 markers as well as notoriously aggressive triple-negative breast cancers.”

Roswell Park has three other studies in progress assessing some of the component elements of this new therapeutic platform:

  • Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients with Colorectal Cancer Metastatic to the Liver (NCT03403634 – actively recruiting)

  • Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT03899987 – authorized by the FDA and Roswell Park’s Internal Review Board; not yet recruiting)

  • Chemokine Modulation Therapy and Pembrolizumab in Treating Participants with Metastatic Triple-Negative Breast Cancer (NCT NCT03599453 – actively recruiting)

AIM ImmunoTech Inc. has agreed to provide rintatolimod for the new DoD-funded studies in brain-metastatic breast cancer, as well as these ongoing studies.

Dr. Kalinski gratefully acknowledges earlier support for his work through donations to Roswell Park as a critical foundation that allowed him to pursue and attract outside funding for this work.

The new study in patients with BMBC is not yet open to accrual. For information about other clinical trials currently available at Roswell Park, please visit roswellpark.org/clinical-trials, call 1-800-ROSWELL (1-800-767-9355) or contact Roswell Park by email at askroswell@roswellpark.org.

This release is also available on the Roswell Park website: https://www.roswellpark.org/media/news/roswell-park-moving-unique-immunotherapy-platform-forward-642-million-dod-grant

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Share article on social media or email:

Business: Insurance

Fargo named division manager for North American Title Co.’s Southern Nevada region

Leave a comment


https://www.prweb.com/

Jeff Fargo, Division Manager, North American Title Co.’s Southern Nevada region

I have long been devoted to helping my customers apply social media, video, data mining and migration patterns to create substantial growth for their businesses and combining these efforts with States Title’s vision for the future of our industry will be a game changer for my customers.


SAN FRANCISCO (PRWEB)

North American Title Co. (NATC) has named Jeff Fargo division manager for its Southern Nevada region. Fargo brings real estate and title insurance experience to his position.

“Jeff’s real estate knowledge and leadership ability makes him uniquely qualified to lead our associates in what promises to be a most rewarding and productive future in this dynamic region,” said Chad Nichols, NATC’s Western region president. “His focus on the customer experience combined with his passion for technology is an excellent complement to our united efforts to build the title company of the future.”

Born into a real estate development family in Upstate New York, Fargo spent much of his early career overseeing his family’s real estate portfolio until moving to St. George, Utah, in 2005. There, he joined Coldwell Banker Commercial KGA as an associate broker. For the past five years, he worked as a marketing executive for First American Title, where, in 2018, he was awarded the national DPK Circle of Excellence award for year-over-year revenue growth.

“As a student of emerging technology, I am beyond excited to join the amazing team that is defining the future for our industry through machine intelligence,” Fargo said. “I have long been devoted to helping my customers apply social media, video, data mining and migration patterns to create substantial growth for their businesses and combining these efforts with States Title’s vision for the future of our industry will be a game changer for my customers.”

NATC is part of the States Title family of companies, a top 10 title insurance and settlement provider. Based in San Francisco, States Title is intelligently transforming closings by applying machine intelligence to make real estate transactions simple and efficient, enhancing the customer experience and enabling loans to close faster and at a lower cost.

Fargo works out of NATC’s Las Vegas office at 8485 W. Sunset Road, Suite 111, Las Vegas, NV 8911392130, and can be reached at (877) 430-6282.

About North American Title

With close to 1,000 associates and a network of branches from coast to coast, North American Title Company (NATC) is among the largest real estate settlement service providers in the United States. Through its relationship with an expanding affiliate network, NATC provides or is able to coordinate real estate settlement services in all 50 states. With more than 100 offices across the country, NATC offers a depth and breadth of local expertise and knowledge in many of the premier real estate markets. NATC’s parent company is States Title Holding Inc., headquartered in San Francisco, California. Founded by Max Simkoff and backed by a significant financial investment from Lennar and leading venture capitalists in Silicon Valley, States Title uses machine intelligence to deliver a simple and efficient title and escrow solution. Learn more at http://www.nat.com.

Share article on social media or email:

Business: Executives

IWCO Direct’s Director of Postal Affairs Elected as New MTAC Industry Vice Chair

Leave a comment


Bob Rosser, IWCO Direct

IWCO Direct’s Bob Rosser has been elected Industry Vice Chair of MTAC.

Bob has dedicated his entire career to mail, and he will be a great champion for members of MTAC, its member associations, and mailing industry stakeholders as he focuses on helping to create a stronger Postal Service.” — Jim Andersen, executive chairman of IWCO Direct


CHANHASSEN, Minn. (PRWEB)

IWCO Direct, a leading provider of data-driven direct marketing solutions, announced Bob Rosser, its Director of Postal Affairs, has been appointed Industry Vice Chair of the Postmaster General’s Mailers’ Technical Advisory Committee (MTAC). Rosser was elected to the position at a recent MTAC meeting and will serve in the role through the end of 2020, when he will become MTAC Industry Chair through the end of 2023.

MTAC is a venue for the United States Postal Service (USPS) to share technical information with mailers, and to receive their advice and recommendations on matters concerning mail-related products and services. MTAC works for the mutual benefit of mailing industry stakeholders and the Postal Service to enhance customer value and expand the use of these products and services. In his new role with MTAC, Rosser aims to focus on keeping the mail channel affordable and providing consistent and predictable mail delivery service. He brings 38 years of experience to his role, during which he has worked with all classes of mailers, and all departments of the USPS, Postal Regulatory Commission, USPS Office of Inspector General, and many trade associations.

Rosser has been with IWCO Direct since 2004, adding to the company’s extensive postal expertise. In addition to its work with MTAC, the company is also involved with APTech, EMA, and PostCom. IWCO Direct works closely with its clients to develop postal strategies that make the most effective use of their mailing budgets and provide more precise in-home delivery dates. The company pioneered the practice of integrated commingling in 1995 and has continued to innovate with optimization techniques like density-driven regional commingling and preparing mail for walk-sequence carrier route discounts.

“IWCO Direct believes it’s important to be an advocate for the mailing industry and to help ensure the Postal Service’s long-term health by helping it adapt to change,” said Jim Andersen, executive chairman of IWCO Direct. “Bob has dedicated his entire career to mail, and he will be a great champion for members of MTAC, its member associations, and mailing industry stakeholders as he focuses on helping to create a stronger Postal Service.”

About IWCO Direct

As a leading provider of data-driven direct marketing solutions, IWCO Direct’s Power your Marketing™ approach drives response across all marketing channels to create new and more loyal customers. The company’s full range of services includes strategy, creative, and execution for omnichannel marketing campaigns, along with one of the industry’s most sophisticated postal logistics strategies for direct mail. Through Mail-Gard®, IWCO Direct offers business continuity and disaster recovery services to protect against unexpected business interruptions, along with providing print and mail outsourcing services. The company is ISO/IEC 27001 Information Security Management System (ISMS) certified through BSI, reflecting its commitment to data security. Stay current on direct marketing trends, industry news, postal regulations, and more by subscribing to IWCO Direct’s SpeakingDIRECT blog.

IWCO Direct is a wholly owned subsidiary of Steel Connect, Inc., a publicly traded diversified holding company (Nasdaq Global Select Market symbol “STCN”); Steel Connect, Inc. has two wholly owned subsidiaries, IWCO Direct and ModusLink Corporation. For more information, please visit About Steel Connect, Inc.

Share article on social media or email: